ATE345788T1 - Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber - Google Patents
Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieberInfo
- Publication number
- ATE345788T1 ATE345788T1 AT02718181T AT02718181T ATE345788T1 AT E345788 T1 ATE345788 T1 AT E345788T1 AT 02718181 T AT02718181 T AT 02718181T AT 02718181 T AT02718181 T AT 02718181T AT E345788 T1 ATE345788 T1 AT E345788T1
- Authority
- AT
- Austria
- Prior art keywords
- virally induced
- treatment
- fever
- inhibitors
- mediated
- Prior art date
Links
- 206010037660 Pyrexia Diseases 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 230000035939 shock Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 4
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 2
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 206010061192 Haemorrhagic fever Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01105552 | 2001-03-06 | ||
| US27464701P | 2001-03-12 | 2001-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345788T1 true ATE345788T1 (de) | 2006-12-15 |
Family
ID=32523996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02718181T ATE345788T1 (de) | 2001-03-06 | 2002-03-06 | Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040122058A1 (de) |
| EP (1) | EP1420778B1 (de) |
| AT (1) | ATE345788T1 (de) |
| AU (1) | AU2002249261A1 (de) |
| WO (1) | WO2002069960A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US7132398B2 (en) | 2003-05-06 | 2006-11-07 | Dendreon Corporation | Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor |
| NZ546011A (en) | 2003-10-21 | 2009-09-25 | Warner Lambert Co | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| DK1691827T3 (da) * | 2004-06-25 | 2009-12-14 | Fibrex Medical Res & Dev Gmbh | Anvendelse af peptider, der er afledt fra beta-kæden af det humane fibrinogen, til behandlling af shock |
| US8232240B2 (en) * | 2005-02-23 | 2012-07-31 | The Brigham And Women's Hospital, Inc. | Inhibitors of enveloped virus infectivity |
| DE102008010362A1 (de) * | 2008-02-18 | 2009-08-20 | Florian Prof. Dr. Lang | Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen |
| JP6189962B2 (ja) | 2012-10-09 | 2017-08-30 | ザ プロクター アンド ギャンブル カンパニー | 相乗作用する美容成分の組み合わせを特定する方法 |
| US10302630B2 (en) | 2012-10-09 | 2019-05-28 | The Procter & Gamble Company | Method of identifying or evaluating beneficial actives and compositions containing the same |
| US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
| US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111529532A (zh) * | 2020-05-05 | 2020-08-14 | 华中科技大学同济医学院附属协和医院 | 曲美替尼在制备治疗肺部炎症性疾病药物及促进Tfh细胞分化药物中的应用 |
| EP3912623B1 (de) * | 2020-05-20 | 2024-07-31 | Atriva Therapeutics GmbH | Pd-0184264 zur behandlung von coronavirus-infektionen und/oder covid-19-cytokin-sturm |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| AU5610398A (en) * | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| WO2000040237A1 (en) * | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| AU3631500A (en) * | 1999-03-19 | 2000-10-09 | Du Pont Pharmaceuticals Company | N-adamant-1-yl-n'-(4-chlorobenzothiazol-2-yl) urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent |
| AU3761400A (en) * | 1999-03-19 | 2000-10-09 | Du Pont Pharmaceuticals Company | Amino-thio-acrylonitriles as mek inhibitors |
-
2002
- 2002-03-06 EP EP02718181A patent/EP1420778B1/de not_active Expired - Lifetime
- 2002-03-06 US US10/469,904 patent/US20040122058A1/en not_active Abandoned
- 2002-03-06 WO PCT/EP2002/002467 patent/WO2002069960A2/en not_active Ceased
- 2002-03-06 AT AT02718181T patent/ATE345788T1/de not_active IP Right Cessation
- 2002-03-06 AU AU2002249261A patent/AU2002249261A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002069960A3 (en) | 2003-01-03 |
| AU2002249261A1 (en) | 2002-09-19 |
| EP1420778A2 (de) | 2004-05-26 |
| US20040122058A1 (en) | 2004-06-24 |
| WO2002069960A2 (en) | 2002-09-12 |
| EP1420778B1 (de) | 2006-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE345788T1 (de) | Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber | |
| ATE388951T1 (de) | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes | |
| NO20021830L (no) | Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav | |
| NO20052928L (no) | Nye kjemiske forbindelser | |
| ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
| NO20045247L (no) | Nukleosidderivater for behandling av hepatitt C-virusinfeksjon | |
| ATE405840T1 (de) | Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung | |
| DE60219793D1 (de) | Methode zur behandlung von zytokinvermittelten erkrankungen | |
| ATE421512T1 (de) | Inhibitoren von mitotischem kinesin | |
| DE602005023587D1 (de) | Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen | |
| DK1377314T3 (da) | Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner | |
| EP3900717C0 (de) | Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen | |
| SA520420909B1 (ar) | تثبيط بروتين رابط لـ creb (cbp) | |
| ATE336996T1 (de) | Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem | |
| BR112022001025A2 (pt) | Inibidores de calicreína plasmática | |
| ATE446514T1 (de) | VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß | |
| EA200702271A1 (ru) | Ингибиторы белка микросомального транспорта триглицеридов и секреции апо-в | |
| ATE429916T1 (de) | Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme | |
| EA202192454A1 (ru) | Новый ингибитор mek для лечения вирусных и бактериальных инфекций | |
| DE602006020775D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen | |
| ATE443044T1 (de) | Tace inhibitoren | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| NO20010140D0 (no) | Kjemotakse-inhiberende protein av Staphylo-Coccus (CHIPS) og dets anvendelse | |
| EP4247800C0 (de) | N-substituierte 4-(1,3-aryloxazolo-2-yl)phenyl-verbindungen zur behandlung und prophylaxe von hepatitis-b-virusinfektionen | |
| DE60219940D1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |